Predictive value of suPAR in AKI: a systematic review and meta-analysis
Open Access
- 5 December 2022
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (1) , 1-11
Abstract
Background Some clinical trials have shown that soluble urokinase-type plasminogen activator receptor (suPAR) has good predictive value for acute kidney injury (AKI), but there is still a lack of evidence-based proof. Therefore, we conducted this systematic review and meta-analysis to evaluate the predictive value of suPAR for AKI. Methods Pubmed, EMBASE, Cochrane Library, and Web of Science databases were searched until December 2021 to obtain the literature on the prediction of suPAR for AKI. The quality of the included studies was assessed using the QUADAS-2 scoring system, and a bivariate random-effect model was used for the meta-analysis. The present study has been registered on PROSPERO (Registration No. CRD42022324978). Results Seven articles were included, involving 2,319 patients, 635 of whom were AKI patients. The meta-analysis results showed that the combined sensitivity of suPAR in predicting AKI was 0.77 (95% CI 0.67–0.84); the specificity was 0.64 (95% CI 0.53–0.75); the odds ratio of diagnosis was 6 (95% CI 3–10); the pooled positive likelihood ratio was 2.2 (95% CI 1.6–2.9); the pooled negative likelihood ratio was 0.36 (95% CI 0.26–0.52); and the area under the summary receiver-operating characteristic (SROC) curve was 0.77 (95% CI 0.12~0.99). Deek’s funnel plot suggested no potential publication bias among included studies. Conclusion suPAR is a valuable biomarker for the prediction of AKI with relatively high predictive accuracy, but its clinical application needs improvements. SuPAR should be considered as an indicator in the subsequent development of more effective predictive tools for AKI.Keywords
Funding Information
- Peak Climbing Project of Foshan Hospital of Traditional Chinese Medicine (202000205)
This publication has 30 references indexed in Scilit:
- Soluble Urokinase Receptor and Chronic Kidney DiseaseNew England Journal of Medicine, 2015
- Ongoing Clinical Trials in AKIClinical Journal of the American Society of Nephrology, 2012
- Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challengesClinical Kidney Journal, 2012
- NoticeKidney International Supplements, 2012
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV‐infected patients receiving highly active antiretroviral therapyJournal of Medical Virology, 2007
- Modification of kidney barrier function by the urokinase receptorNature Medicine, 2007
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Assessing Kidney Function — Measured and Estimated Glomerular Filtration RateNew England Journal of Medicine, 2006
- Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) GroupCritical Care, 2004